VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. - Wikidata - thesis-toulmin - TriplyDB

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

http://www.wikidata.org/entity/Q39959426

about

Medical treatment for gastro-entero-pancreatic neuroendocrine tumours The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation Tumor stroma as targets for cancer therapy Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting Role of platelet-derived growth factors in physiology and medicine Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2 Synthetic antibodies as therapeutics.Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression Inoculated mammary carcinoma-associated fibroblasts: contribution to hormone independent tumor growth.An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature.VEGF-independent angiogenic pathways induced by PDGF-C.Anti-angiogenic agents in the treatment of non-small cell lung cancer.Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma Phase I study of olaratumab in Japanese patients with advanced solid tumors.Endothelial cells, fibroblasts and vasculitis Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer.Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis Growth factors in ischemic stroke.Identification of alterations in DNA copy number in host stromal cells during tumor progression The role of the cell-cell interactions in cancer progression.Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.Pancreatic cancer stromal biology and therapy.Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up.Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment.Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis.Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.

P2860

Q26751659-CB1CD86F-2F72-4D60-BC46-E3B7D6AAF250 Q26778930-7451BFD7-24D6-496D-854E-A69684D6C5D1 Q27015980-3F1E2184-6641-467D-9D09-986DDE142BD6 Q28269990-D5AE6965-1C93-40E8-B7F7-874E4DDDDF37 Q28755868-B0742AC7-42DC-4577-96E2-5D968678B206 Q29615222-3FDF2246-8BB3-4B0E-A0D9-35B22452F5B6 Q30438929-40294799-175F-4BF0-96BD-C06F5B973C8A Q33265617-124E05AB-0FD6-4C5D-ABF3-161BBB67B7C6 Q33427809-B94734AA-F793-4087-90AF-52BFB4D6E913 Q33606201-C2FDF7B0-AE88-4610-A519-BCAAEE158F9E Q33751487-BC58C1BE-674D-43A5-B4B7-0BFBA167DB23 Q34149273-EC5BB6B4-81FF-47B6-BD6D-D13B7AA72934 Q34821321-A54CE6C4-CDE1-4BC8-8680-EB74C8D40AE3 Q34979357-67C4223D-75EE-434E-8B26-22C2D97AB081 Q35051852-574BFB94-EEC6-4B34-8D54-67EA808E06EC Q35058025-F0BA63B3-06F3-4BC2-BE62-BE1C60BE1E49 Q35059600-AD0C0E36-4FCA-456C-AE51-FB48475FF6EC Q35082777-F9092C7F-BF76-4A66-9053-D0BDCED96FAB Q35163538-49C1ADB9-53CA-4159-A651-8806F131BB9D Q35196919-E4F2940D-CA6B-4EBF-8D29-985771B90F76 Q35216143-F63A8E42-441C-4C1B-89E6-915BF06CFA49 Q35222185-722B1AFE-7993-43F5-93A1-3C4F932313F0 Q35531372-42373BA3-1896-4499-BA55-B37C858B660C Q35633850-CC9E85DB-C98D-491D-A0E1-638113F218C7 Q35766799-2EA41915-B0BD-4B18-9F64-F7754EBE1874 Q35781386-3D58B616-617E-4B5A-986D-EA662E133593 Q35782469-50213170-7FC1-4133-A3DA-2302C7411EF8 Q36094989-BF206AB1-D527-4030-9301-E30C4CF609D6 Q36161541-30A3BD3E-DC79-4C18-A942-8438F79CF260 Q36187025-A6BD0483-303D-46C9-A091-101E62FD76AF Q36289382-0F28809E-6FAF-4B7E-8282-EA395400FF30 Q36322742-0D098470-B0FD-4BF2-92AD-D64E10E9DDB4 Q36357356-9F9F9C43-12CB-4D20-93C6-498B49C3B3E4 Q36387788-8DBC7E41-6CE0-4899-9315-86B658491E85 Q36392642-FA3AD7E8-6541-4DAB-BA42-CE7A17CE4C05 Q36413809-2D1A4E1F-46CA-4B65-A7FF-ECE4D0796FD2 Q36508627-AD283EEB-DE9F-41B0-AFD7-64E083C6F12D Q36627144-BCA3E4CC-4F4F-4791-ABBB-865F13E2974A Q36676685-A993FD17-9F1A-47D3-A37D-794817A804A7 Q36691776-D7CB5390-F42F-4173-9DA2-EC5C79B1BA26

P2860

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

http://www.wikidata.org/entity/Q39959426

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@en

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@nl

type

label

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@en

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@nl

prefLabel

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@en

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@nl

P1433

Q39959426-4CE41EC3-0181-4FF2-A73F-61BBE7B1A3E8

P1476

Q39959426-43915DA0-8A78-4C92-83F7-450500C1D973

P2093

Q39959426-1A0F45A2-EBE0-433C-8255-C0CA6770095D

Q39959426-368F32A1-F667-4378-965D-0C6EB64B795F

Q39959426-419DDC67-D9F2-4E00-AD21-0816FD1978A5

Q39959426-57395FE0-299E-4136-B2DF-FAD87C23AD91

Q39959426-59D05DAA-2F7C-4993-863B-7904B08B6690

Q39959426-6A678647-7BB7-4158-936A-EAA77447ABCE

Q39959426-7DD0047B-9556-46A6-86E3-DE29B4EAF72F

Q39959426-8D87D12F-8120-4723-873F-74536969444E

Q39959426-BCCBCF5A-FDE4-4810-B070-DA9A4631466B

Q39959426-D149E8B1-4474-4E43-A0F5-A3E9E177F3E3

P2860

Q39959426-03F60F98-A670-43EB-9017-918F374BA1F1

Q39959426-0F5237A5-282E-45B2-8DAB-1CF1C589B3D4

Q39959426-2C9BDDD0-C972-4F5D-A79E-A6C1D6EDBD49

Q39959426-33B428A9-4BF0-4BCD-8B20-F3622A5C6CE8

Q39959426-36A5D387-9248-43B6-9CF7-E60026794120

Q39959426-3B20A306-7170-456E-B4E2-B64AF865FE06

Q39959426-40B81BEE-07C6-4A90-8F87-95FF2371F9AF

Q39959426-49B3D271-9F3C-4836-8AFC-DC153636F019

Q39959426-4F9EC1ED-D884-40CF-BFAF-57C303D83926

Q39959426-54477DBE-8694-4875-ACBD-B88105FC88F2

P304

Q39959426-BA237055-BEBD-4967-AEAE-CE96E35A6365

P31

Q39959426-318E99F0-0536-45CB-A869-AFFC3C434774

P356

Q39959426-B9FE8835-4B49-48D8-918F-451A8C345521

P407

Q39959426-C02327D7-FBF6-422B-A26E-CF019EC31FD2

P433

Q39959426-1DC1BCB0-5BFE-4863-BFC1-20F872A64F2B

P478

Q39959426-95BA0CF0-9F62-432B-ACF5-3F533B8D40ED

P577

Q39959426-70F9EA81-EE2A-438A-B56A-1A68B6DDD759

P5875

Q39959426-5825F1C9-2F94-4638-8F8F-0C1B0A172405

P698

Q39959426-6F1CBE51-C03D-41AF-855A-FE4214F012D0

P932

Q39959426-557611D3-B1D3-422C-A223-2881A4512646

P356

SJ.EMBOJ.7600289

P1433

The EMBO Journal

P1476

VEGF-null cells require PDGFR ...... recruitment for tumorigenesis.

@en

P2093

Frank Peale

http://www.w3.org/2001/XMLSchema#string

Germaine Fuh

http://www.w3.org/2001/XMLSchema#string

Gretchen Frantz

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Gerber

http://www.w3.org/2001/XMLSchema#string

Jeremy Grunstein

http://www.w3.org/2001/XMLSchema#string

Jianying Dong

http://www.w3.org/2001/XMLSchema#string

Joe Kowalski

http://www.w3.org/2001/XMLSchema#string

Lanlan Yu

http://www.w3.org/2001/XMLSchema#string

Max Tejada

http://www.w3.org/2001/XMLSchema#string

Napoleone Ferrara

http://www.w3.org/2001/XMLSchema#string

P2860

PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor

Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

The biology of VEGF and its receptors

Angiogenesis in cancer and other diseases

Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor

Angiogenesis in cancer, vascular, rheumatoid and other disease

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

P304

2800-2810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.EMBOJ.7600289

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8478291

http://www.w3.org/2001/XMLSchema#string

P698

15229650

http://www.w3.org/2001/XMLSchema#string

P932

514949

http://www.w3.org/2001/XMLSchema#string